外科理论与实践

外科理论与实践 >

2020 , Vol. 25 >Issue 05: 373 - 377

DOI: https://doi.org/10.16139/j.1007-9610.2020.05.004

专家论坛

减重代谢手术对肥胖型非酒精性脂肪肝治疗的意义

展开
  • 复旦大学附属华山医院普外科,上海 200040

收稿日期: 2020-09-16

  网络出版日期: 2022-07-27

收起

Impact of bariatric and metabolic surgery on nonalcoholic fatty liver disease

Expand

Received date: 2020-09-16

  Online published: 2022-07-27

Fold

本文引用格式

花荣, 姚琪远 . 减重代谢手术对肥胖型非酒精性脂肪肝治疗的意义[J]. 外科理论与实践, 2020 , 25(05) : 373 -377 . DOI: 10.16139/j.1007-9610.2020.05.004

参考文献

[1] NCD Risk Factor Collaboration(NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026):1377-1396.
[2] Chalasani N, Younossi Z, Lavine J, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6):2005-2023.
[3] Kleiner DE, Brunt EM, van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6):1313-1321.
[4] Borges-Canha M, Neves JS, Mendonça F, et al. The impact of bariatric surgery on hepatic function and predictors of liver steatosis and fibrosis[J]. Obes Surg, 2020, 30(8):2935-2941.
[5] Younossi Z, Koenig A, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
[6] Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver di-sease: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2008, 6(12):1396-1402.
[7] Udelsman BV, Corey KE, Lindvall C, et al. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery[J]. Surg Obes Relat Dis, 2019, 15(6):843-849.
[8] Portillo Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels[J]. J Clin Endocrinol Metab, 2015, 100(6):2231-2238.
[9] Agopian VG, Kaldas FM, Hong JC. Live transplantation for nonalcoholic steatohepatitis: the new epidemic[J]. Ann Surg, 2012, 256(4):624-633.
[10] Salman MA, Mikhail HMS, Nafea MA, et al. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis[J]. Surg Endosc, 2020. doi: 10.1007/s00464-020-07498-4.
[11] Younus H, Sharma A, Miquel R, et al. Bariatric surgery in cirrhotic patients: is it safe?[J]. Obes Surg, 2020, 30(4):1241-1248.
[12] Lazzati A, Iannelli A, Schneck AS, et al. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery[J]. Obes Surg, 2015, 25(1):134-142.
[13] Ayloo S, Gussa C, Ram S, et al. Minimally invasive sleeve gastrectomy as a surgical treatment for nonalcoholic fatty liver disease in liver transplant recipients[J]. Transplant Proc, 2020, 52(1):276-283
[14] Gasteyger C, Larsen TM, Vercruysse F, et al. Effect of a dietary induced weight loss on liver enzymes in obese subjects[J]. Am J Clin Nutr, 2008, 87(5):1141-1147.
[15] Baltasar A, Serra C, Perez N, et al. Clinical hepatic impairment after the duodenal switch[J]. Obes Surg, 2004, 14(1):77-83.
[16] Requarth JA, Burchard KW, Colacchio TA, et al. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal[J]. Arch Surg, 1995, 130(3):318-325.
[17] Eilenberg M, Langer FB, Beer A, et al. Significant liver-related morbidity after bariatric surgery and its reversal-a case series[J]. Obes Surg, 2018, 28(3):812-819.
[18] Sugerman HJ, Kellum JM, DeMaria EJ. Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity[J]. J Gastrointest Surg, 1997, 1(6):517-524, discussion 524-526.
[19] Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria[J]. Surg Obes Relat Dis, 2019, 15(12):2123-2130.
[20] Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis[J]. Surg Obes Relat Dis, 2019, 15(3):502-511.
[21] Kwak M, Mehaffey JH, Hawkins RB, et al. Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis[J]. Am J Surg, 2020, 219(3):504-507.
[22] Wirth KM, Sheka AC, Kizy S, et al. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis[J]. Ann Surg, 2020, 272(1):32-39.
[23] Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease[J]. Gastroenterology, 2014, 146(3):726-735.
[24] Tannapfel A, Denk H, Dienes HP, et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease[J]. Virchows Arch, 2011, 458(5):511-523.
[25] Jacome-Sosa MM, Parks EJ. Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans[J]. Curr Opin Lipidol, 2014, 25(3):213-220.
[26] Day CP, James OF. Steatohepatitis: a tale of two “hits”[J]. Gastroenterology, 1998, 114(4):842-845.
[27] Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2014, 46(4):352-356.
[28] Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter[J]. Hepatology, 2010, 52(6):1992-2000.
[29] Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147(4):765-783.e4.
[30] Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis[J]. Clin Liver Dis, 2009, 13(4):545-563.
[31] Seki E, de Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis[J]. Nat Med, 2007, 13(11):1324-1332.
[32] Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes[J]. N Engl J Med, 2017, 376(7):641-651.
[33] Leonetti F, Capoccia D, Coccia F, et al. Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs. medical treatment[J]. Arch Surg, 2012, 147(8):694-700.
[34] Hua R, Wang GZ, Shen QW, et al. Sleeve gastrectomy ameliorated HFD-induced non-alcoholic fatty liver di-sease and upregulated the nicotinamide adenine dinucleotide +/Sirtuin-1 pathway in mice[J]. Asian J Surg,2020-07-22.doi: 10.1016/j.asjsur.2020.05.030.
[35] Jørgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance[J]. Am J Physiol Endocrinol Metab, 2012, 303(1):E122-E131.
[36] Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis[J]. Liver Int, 2011, 31(9):1285-1297.
[37] Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans[J]. Obes Surg, 2014, 24(2):241-252.
[38] Whang W, Liu Y, Kageyama S, et al. Vertical sleeve gastrectomy attenuates the progression of non-alcoholic steatohepatitis in mice on a high-fat high-cholesterol diet[J]. Obes Surg, 2019, 29(8):2420-2429.
[39] Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism[J]. Obesity (Silver Spring), 2009, 17(9):1671-1677.
[40] Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery[J]. Metabolism, 2009, 58(10):1400-1407.
[41] Huang HH, Lee WJ, Chen SC, et al. Bile acid and fibroblast growth factor 19 regulation in obese diabetics, and non-alcoholic fatty liver disease after sleeve gastrectomy[J]. J Clin Med, 2019, 8(6):815-829.
[42] Fei N, Bruneau A, Zhang X, et al. Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease[J]. mBio, 2020, 11(1):e03263-19.
Options
文章导航

/

〈 〉